Rollins K, Noorani A, Janeckova L, Jones T, Griffiths M, Baker M P, Boyle J R
National Institute for Health Research Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, UK.
Cambridge Vascular Unit, Addenbrookes Hospital, Cambridge, UK.
BMC Nephrol. 2017 Mar 24;18(1):101. doi: 10.1186/s12882-017-0498-5.
Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid (AA) has a nephroprotective effect in percutaneous coronary interventions when contrast media are used. A variety of biomarkers (NGAL, NGAL:creatinine, mononuclear cell infiltration, apoptosis and RBP-4) in both the urine and kidney were assayed using a mouse model of CIN in order to determine whether AA can reduce the incidence and/or severity of renal injury.
Twenty-four BALB/c mice were divided into 4 groups. Three groups were exposed to high doses of contrast media (omnipaque) in a well-established model of CIN, and then treated with low or high dose AA or placebo (saline). CIN severity was determined by measurement of urinary neutrophil gelatinase-associated lipocalin (NGAL):creatinine at specific time intervals. Histological analysis was performed to determine the level of mononuclear inflammatory infiltration as well as immunohistochemistry to determine apoptosis in the glomeruli by staining for activated caspase-3 and DNA nicking (TUNEL assays). Reverse transcriptase PCR (rtPCR) of mRNA transcripts prepared from mRNA extracted from mouse kidneys was also performed for both lipocalin-2 (Lcn2) encoding NGAL and retinol binding protein-6 (RBP4) genes. NGAL protein expression was also confirmed by ELISA analysis of kidney lysates.
Urinary NGAL:creatinine ratio was significantly lower at 48 h with a 44% and 62% (204.3μg/mmol versus 533.6μg/mmol, p = 0.049) reduction in the low and high dose AA groups, respectively. The reduced urinary NGAL:creatinine ratio remained low throughout the time period assessed (up to 96 h) in the high dose AA group. In support of the urinary analysis ELISA analysis of NGAL in kidney lysates also showed a 57% reduction (12,576 ng/ml versus 29,393 ng/ml) reduction in the low dose AA group. Immunohistochemistry for apoptosis demonstrated decreased TUNEL and caspase-3 expression in both low and high dose AA groups.
Ascorbic acid reduced the frequency and severity of renal injury in this murine model of CIN. Further work is required to establish whether AA can reduce the incidence of CIN in humans undergoing endovascular procedures.
造影剂诱导的肾病(CIN)是医源性肾损伤最常见的原因,随着复杂血管内介入手术的出现,其发病率有所上升。有证据表明,在使用造影剂的经皮冠状动脉介入治疗中,抗坏血酸(AA)具有肾脏保护作用。为了确定AA是否能降低肾损伤的发生率和/或严重程度,我们使用CIN小鼠模型对尿液和肾脏中的多种生物标志物(中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、NGAL与肌酐比值、单核细胞浸润、细胞凋亡和视黄醇结合蛋白4(RBP-4))进行了检测。
将24只BALB/c小鼠分为4组。在一个成熟的CIN模型中,3组小鼠接受高剂量造影剂(欧乃派克),然后分别用低剂量或高剂量AA或安慰剂(生理盐水)进行治疗。通过在特定时间间隔测量尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)与肌酐比值来确定CIN的严重程度。进行组织学分析以确定单核细胞炎症浸润水平,并通过活化半胱天冬酶-3染色和DNA缺口(TUNEL检测)进行免疫组织化学分析以确定肾小球中的细胞凋亡情况。还对从小鼠肾脏提取的mRNA制备的mRNA转录本进行逆转录聚合酶链反应(rtPCR),检测编码NGAL的脂质运载蛋白2(Lcn2)和视黄醇结合蛋白6(RBP4)基因。通过对肾脏裂解物进行ELISA分析也证实了NGAL蛋白的表达。
在48小时时,低剂量和高剂量AA组的尿NGAL与肌酐比值显著降低,分别降低了44%和62%(204.3μg/mmol对533.6μg/mmol,p = 0.049)。在整个评估时间段(长达96小时)内,高剂量AA组降低的尿NGAL与肌酐比值一直保持在较低水平。支持尿液分析的是,对肾脏裂解物中NGAL的ELISA分析也显示低剂量AA组降低了57%(12,576 ng/ml对29,393 ng/ml)。细胞凋亡的免疫组织化学分析表明,低剂量和高剂量AA组的TUNEL和半胱天冬酶-3表达均降低。
在这个CIN小鼠模型中,抗坏血酸降低了肾损伤的发生率和严重程度。需要进一步开展研究以确定AA是否能降低接受血管内介入手术的人类患者中CIN的发生率。